Pharmaceutical Companies

The proposed expansion would allow its use in adolescents aged 12 to 17 years with moderate to severe chronic hand eczema (CHE) when topical corticosteroids are inadequate or inappropriate.

Under the agreement, 1ST Biotherapeutics will receive US$1.8 million upfront and an additional US$1.8 million payment in the near term.

Roche will take responsibility for subsequent development activities, including preclinical research, and oversee the programmes as they progress towards potential commercialisation.

The new company combines Kincell’s expertise in immune-cell technologies with Cellipont’s experience in stem cells, induced pluripotent stem cells (iPSCs), mesenchymal stromal cells (MSCs), dendritic cells, exosomes and emerging messenger RNA (mRNA) technologies.

The deal builds on a relationship between the companies that began in 2014, including previous transfers of mature medicines from Sanofi to Cheplapharm.

Under the new agreement, Ori will work with its partner to modernise the manufacturing process for an autologous cell therapy.

QurCan will focus on developing and optimising genetic therapeutics using its delivery technology, while Lilly will take responsibility for advancing selected candidates through subsequent development stages.

The partnership complements existing mechanisms for supplying generic versions of lenacapavir and aims to address gaps in HIV prevention across the region.

Developed by Curium, Bexlutry is a lutetium-177 dotatate injection that references Novartis’ Lutathera, which is approved to treat gastroenteropancreatic neuroendocrine tumors (GEP NETs).

GSK will take full global rights to the experimental TCE programme in return for an upfront payment and potential development and commercial milestone payments.